IL323103A - נגזרות אדנין לעיכוב hsp90 - Google Patents
נגזרות אדנין לעיכוב hsp90Info
- Publication number
- IL323103A IL323103A IL323103A IL32310325A IL323103A IL 323103 A IL323103 A IL 323103A IL 323103 A IL323103 A IL 323103A IL 32310325 A IL32310325 A IL 32310325A IL 323103 A IL323103 A IL 323103A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- methyl
- disease
- compound according
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23305369 | 2023-03-17 | ||
| PCT/EP2024/056937 WO2024194175A1 (en) | 2023-03-17 | 2024-03-15 | Adenine derivatives as hsp90 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323103A true IL323103A (he) | 2025-11-01 |
Family
ID=85792333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323103A IL323103A (he) | 2023-03-17 | 2025-09-02 | נגזרות אדנין לעיכוב hsp90 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4680606A1 (he) |
| JP (1) | JP2026509913A (he) |
| KR (1) | KR20250158770A (he) |
| AU (1) | AU2024239653A1 (he) |
| IL (1) | IL323103A (he) |
| WO (1) | WO2024194175A1 (he) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| CA2786715C (en) * | 2009-01-16 | 2019-05-21 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| ES2647889T3 (es) * | 2011-04-05 | 2017-12-27 | Sloan-Kettering Institute For Cancer Research | Inhibidores de la Hsp90 |
| WO2023006993A1 (en) * | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
-
2024
- 2024-03-15 WO PCT/EP2024/056937 patent/WO2024194175A1/en not_active Ceased
- 2024-03-15 EP EP24710769.1A patent/EP4680606A1/en active Pending
- 2024-03-15 KR KR1020257031888A patent/KR20250158770A/ko active Pending
- 2024-03-15 JP JP2025554204A patent/JP2026509913A/ja active Pending
- 2024-03-15 AU AU2024239653A patent/AU2024239653A1/en active Pending
-
2025
- 2025-09-02 IL IL323103A patent/IL323103A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250158770A (ko) | 2025-11-06 |
| JP2026509913A (ja) | 2026-03-25 |
| EP4680606A1 (en) | 2026-01-21 |
| AU2024239653A1 (en) | 2025-10-09 |
| WO2024194175A1 (en) | 2024-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10344031B2 (en) | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | |
| US9782391B2 (en) | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | |
| US9688654B2 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| US20120071475A1 (en) | Urea derivatives having pi3k-inhibiting activity | |
| IL294136A (he) | תרכובת פיירידאזינייל-תיאזולקרבואקסמיד | |
| IL266547A (he) | מעכבי magl | |
| IL295393A (he) | מאפנני p2x3 | |
| NZ576234A (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
| JP2024510274A (ja) | アミノヘテロアリール化合物および組成物 | |
| IL268010A (he) | תרכובת פירימידין ושימוש רוקחי שלה | |
| IL266483A (he) | מאפננים חדשים של 5-הידרוקסיטריפטאמין קולטן 7 ושיטה לשימוש בהם | |
| AU2019375825A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| JP2026042774A (ja) | Ｃｄｋキナーゼ阻害剤として使用される化合物およびその応用 | |
| IL259297B (he) | תרכובות הטרוציקליות לטיפול במחלה | |
| IL291114B1 (he) | תרכובת פירימידין ושיטה להכנתה | |
| KR20250083557A (ko) | Ahr 효능제 | |
| IL323103A (he) | נגזרות אדנין לעיכוב hsp90 | |
| TW201639836A (zh) | 二氮雜－苯並熒蒽類化合物 | |
| JP2024521231A (ja) | ＰｒＰＣのモジュレーター及びその使用 | |
| IL312896A (he) | מעכב 15-pgdh ושימוש בו | |
| CN110494432A (zh) | 异喹啉化合物，其制备方法及其在与β-半乳糖苷酶活性改变相关的病症中的治疗用途 | |
| KR20250047747A (ko) | 에모파밀 결합 단백질 억제제 및 이의 용도 | |
| JP2025504889A (ja) | エモパミル結合タンパク質阻害剤及びその使用 | |
| WO2025172706A1 (en) | Compounds modulating flap endonuclease (fen1) | |
| KR20240046553A (ko) | Sting 길항제로서의 소분자 우레아 유도체 |